Developer docs
API playgroundTry for free, no card

Search company profiles

Arix Bioscience

Full company profile

uuid0005b3d

Namestring
Arix Bioscience
Websiteurl
arixbioscience.com
Company typeenum
Private
Founded yearint
2015
Short descriptiontext

Arix Bioscience is a London-based, LSE-listed venture capital firm founded in 2015 that historically invested in global breakthrough biotechnology companies. Its corporate domain is currently parked, and its leadership includes an interim finance director, suggesting contraction or wind-down.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
venture capital, biotechnology investment, life sciences financing, healthcare venture, breakthrough therapeutics
Industry1 code
1Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryYes
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Biotechnology Venture Capital
Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Arix Bioscience is a publicly listed global venture capital company that invests in and supports breakthrough biotechnology companies. The firm deploys capital into life sciences ventures and works with portfolio companies to build value, typically providing strategic, operational, and scientific guidance alongside equity financing.

Differentiator
Functional benefit
Problem solved
No data
Peers8 records
1PureTech Health
TypeDirect peer
Description

PureTech Health is a London-listed biotech company that both develops internal therapeutics and holds stakes in founded entities — overlapping with Arix's model of building and investing in breakthrough biotech ventures.

2Syncona
TypeDirect peer
Description

Syncona is a London-listed (SYNC.L) healthcare and biotech investment company that builds and backs life-sciences companies — the closest direct peer to Arix in structure, strategy, and geography.

3Forbion
TypeBroad incumbent
Description

Forbion is a leading European life-sciences VC firm managing multiple billion-Euro funds; comparable to Arix as a specialist biotech investor, though larger and operating as a private partnership.

4Sofinnova Partners
TypeBroad incumbent
Description

Sofinnova is one of Europe's largest independent biotech-specialist venture capital firms based in Paris; a broad incumbent peer with overlapping biotech sector focus though operating as a traditional private fund manager rather than a listed company.

5International Biotechnology Trust
TypeDirect peer
Description

IBT is a UK-listed investment trust focused on quoted and unquoted biotechnology companies; a close structural peer to Arix as a publicly traded biotech-focused investment vehicle.

6Lundbeckfonden / Lundbeckfonden Ventures
TypeBroad incumbent
Description

Lundbeckfonden is a Danish-based commercial foundation that invests broadly in biotech and life sciences through its venture arm; comparable to Arix in its focus on European biotech innovation and sector specialization.

7RTW Investments
TypeEmerging player
Description

RTW Investments is a New York-based specialist biotech and healthcare investment manager with both public and private fund strategies — comparable to Arix in its sector specialization and dual public/private exposure.

8BB Biotech
TypeDirect peer
Description

BB Biotech is a Swiss-listed investment company holding a concentrated portfolio of biotech equities; comparable to Arix as a publicly traded vehicle providing liquid biotech exposure, though it primarily invests in public equities rather than private companies.

Market position
Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment32 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arix Bioscience

Biotechnology Venture Capitalarixbioscience.com

Arix Bioscience is a London-based, LSE-listed venture capital firm founded in 2015 that historically invested in global breakthrough biotechnology companies. Its corporate domain is currently parked, and its leadership includes an interim finance director, suggesting contraction or wind-down.

Arix Bioscience firmographics

Firmographics
Name
Arix Bioscience
Website
https://arixbioscience.com
Company type
Private
Founded year
2015
Headcount range
11–50 employees
Short description
Arix Bioscience is a London-based, LSE-listed venture capital firm founded in 2015 that historically invested in global breakthrough biotechnology companies. Its corporate domain is currently parked, and its leadership includes an interim finance director, suggesting contraction or wind-down.
Ownership category
akta.pro rank

Arix Bioscience industry classification

Industry
Product category
Biotechnology Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro primary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

  • Venture capital
  • Biotechnology investment
  • Life sciences financing
  • Healthcare venture
  • Breakthrough therapeutics

Where Arix Bioscience is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Arix Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Arix Bioscience product offering

Product offering

Core offering

Arix Bioscience is a publicly listed global venture capital company that invests in and supports breakthrough biotechnology companies. The firm deploys capital into life sciences ventures and works with portfolio companies to build value, typically providing strategic, operational, and scientific guidance alongside equity financing.

Differentiator

Problem solved

Functional benefit

Companies that use Arix Bioscience

Customer profile

Ideal customer profiles2 records

Arix Bioscience technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Arix Bioscience competitors and assessment

Company assessment

Direct peers

  • PureTech Health: PureTech Health is a London-listed biotech company that both develops internal therapeutics and holds stakes in founded entities — overlapping with Arix's model of building and investing in breakthrough biotech ventures.
  • Syncona: Syncona is a London-listed (SYNC.L) healthcare and biotech investment company that builds and backs life-sciences companies — the closest direct peer to Arix in structure, strategy, and geography.
  • International Biotechnology Trust: IBT is a UK-listed investment trust focused on quoted and unquoted biotechnology companies; a close structural peer to Arix as a publicly traded biotech-focused investment vehicle.
  • BB Biotech: BB Biotech is a Swiss-listed investment company holding a concentrated portfolio of biotech equities; comparable to Arix as a publicly traded vehicle providing liquid biotech exposure, though it primarily invests in public equities rather than private companies.

Broad incumbents

  • Forbion: Forbion is a leading European life-sciences VC firm managing multiple billion-Euro funds; comparable to Arix as a specialist biotech investor, though larger and operating as a private partnership.
  • Sofinnova Partners: Sofinnova is one of Europe's largest independent biotech-specialist venture capital firms based in Paris; a broad incumbent peer with overlapping biotech sector focus though operating as a traditional private fund manager rather than a listed company.
  • Lundbeckfonden / Lundbeckfonden Ventures: Lundbeckfonden is a Danish-based commercial foundation that invests broadly in biotech and life sciences through its venture arm; comparable to Arix in its focus on European biotech innovation and sector specialization.

Emerging players

  • RTW Investments: RTW Investments is a New York-based specialist biotech and healthcare investment manager with both public and private fund strategies — comparable to Arix in its sector specialization and dual public/private exposure.

Market position

Customer concentration

Arix Bioscience social profiles

Digital presence

Arix Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arix Bioscience leadership team

Management profile

Number of profiles

Profiles5 records

Arix Bioscience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arix Bioscience M&A and investment

M&A and investment

M&A

Investments32 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arix Bioscience

What does Arix Bioscience do?

Arix Bioscience is a publicly listed global venture capital company that invests in and supports breakthrough biotechnology companies. The firm deploys capital into life sciences ventures and works with portfolio companies to build value, typically providing strategic, operational, and scientific guidance alongside equity financing.

When was Arix Bioscience founded?

Arix Bioscience was founded in 2015. It employs 11 to 50 people.

Where is Arix Bioscience based?

Arix Bioscience is headquartered in London, United Kingdom, in the Europe region.

Who are Arix Bioscience's main competitors?

Direct peers on record are PureTech Health, Syncona, International Biotechnology Trust and BB Biotech. Broad incumbents are Forbion, Sofinnova Partners and Lundbeckfonden / Lundbeckfonden Ventures. RTW Investments is listed as an emerging player.

Does Arix Bioscience have an API?

No public API is recorded for Arix Bioscience.

What industry is Arix Bioscience in?

Arix Bioscience's product category is Biotechnology Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerSorriso Pharmaceuticals, Inc. announced that it has received $31 million in funding from New Enterprise Associates, Inc., Arix Bioscience plc and other investorsSorriso Pharmaceuticals, Inc. announced that it has received $31 million in funding from New Enterprise Associates, Inc., Arix Bioscience plc, and other investors. This capital injection supports the company's development activities as part of its strategic financing efforts.PR NewswireArix Bioscience plc: Arix to Present at the Proactive One2One Biotech ForumArix Bioscience plc announced that Managing Director Jonathan Tobin will present at the Proactive One2One Virtual Biotech Forum on June 11, 2020. The company will be the first of four presenting companies at the webinar, which will include a presentation followed by a Q&A session. A replay will be available on the company's investor relations website after the event.PR NewswireArix to Participate in Fireside Chat at the Jefferies Virtual Healthcare ConferenceArix Bioscience plc announced that Jonathan Tobin, Managing Director, is scheduled to participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 11am EDT/4pm BST. A live webcast of the event will be available on the investor relations section of Arix's website, with an archived replay to follow. The announcement is a routine investor relations communication regarding a scheduled conference appearance.PR NewswireArix Bioscience plc: Investment Team Changes - Jonathan Tobin, PhD, promoted to Managing DirectorArix Bioscience plc announced changes to its investment team, promoting Jonathan Tobin to Managing Director and John Cassidy to Principal. These moves are part of a broader organizational restructuring aimed at realizing value from the current biotech portfolio and preparing for future growth. Additional board appointments were made for several other executives across the company's portfolio companies.PR NewswireArix Bioscience plc : Imara Files for Proposed Initial Public Offering in the United StatesImara Inc., a clinical-stage biotechnology company and portfolio company of Arix Bioscience plc, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock in the United States. Imara has applied to list on the Nasdaq Global Market under the ticker symbol "IMRA," with the offering's size and terms subject to market conditions and no assurance it will be completed. The proceeds would support advancement of Imara's lead therapy IMR-687, an oral once-daily treatment for sickle cell disease and beta-thalassemia currently in clinical development.PR NewswireArix Bioscience plc: 2019 Capital Markets DayArix Bioscience plc is hosting its 2019 Capital Markets Day on October 3, 2019, in London, focused on its oncology portfolio. The event provides an opportunity for institutional investors, analysts, and media to learn about Arix's strategy and portfolio companies without disclosing new material information. Presenters include Arix executives and leaders from partner companies in the oncology sector.PR NewswireArix Bioscience plc: Amplyx Unveils Expanded Pipeline and Reports Phase 2 Data from Lead ProgrammeAmplyx Pharmaceuticals announced positive preliminary Phase 2 data for its lead antifungal candidate fosmanogepix (APX001) in treating candidemia, with independent review committees confirming high treatment success rates and recommending the study continue. The company also entered into an exclusive worldwide license agreement with Novartis to acquire Phase 2 anti-BK virus monoclonal antibody MAU868 for transplant patients, expanding its pipeline into antiviral treatments.PR NewswireArix Bioscience plc - Imara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering in the United StatesImara, Inc. has confidentially submitted a draft registration statement (Form S-1) to the U.S. Securities and Exchange Commission for a proposed initial public offering in the United States. The announcement was made by Arix Bioscience plc, which identifies Imara as its portfolio company. The timing and terms of the IPO remain undetermined and are subject to market conditions.PR NewswireArix Bioscience plc: Interim Results for the Six Months Ended 30 June 2019Arix Bioscience plc reported a 14.5% decline in Net Asset Value per share for H1 2019, falling to £231.8 million (171p per share) from £270.2 million (200p per share) at end-2018, primarily due to a 51% decline in Autolus Therapeutics' share price despite strong fundamentals. The venture capital firm deployed £26.3 million into its portfolio, including co-leading a $63 million Series B for new portfolio company Imara, and its portfolio companies collectively raised $283 million in aggregate financing rounds. The period resulted in a net loss before tax of £44.8 million versus a £29.3 million profit in H1 2018, though 28 clinical trials were live across the portfolio and multiple companies achieved clinical milestones including Harpoon's Nasdaq IPO and positive data readouts from Autolus, Aura, and Imara.PR NewswireArix Bioscience plc: Imara Presents initial Phase 2a data for IMR-687Imara Inc. presented positive interim Phase 2a data for its investigational drug IMR-687 in the treatment of Sickle Cell Disease at the European Hematology Association Congress in Amsterdam. The results indicated that the therapy was well-tolerated and showed promising trends in key biomarkers, including increased fetal hemoglobin expression. Imara plans to announce additional interim data in the second half of 2019.